Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

New bioimaging collaboration to bolster infectious disease research
The collaboration will greatly improve the UK's national capabilities

Electron microscopes will allow more detailed study of viral diseases

The Pirbright Institute and Diamond Light Source have announced a new-five year collaboration that will allow both institutions to make advancements in their research. This agreement will improve research and innovation identified by the UK Research and Innovation (UKRI) infrastructure programme.

Pirbright’s head of bioimaging Professor Pippa Hawes will be working at both sites, helping to prepare Pirbright research projects for high resolution electron microscopy and contributing to Diamond’s development initiatives.

Commenting on the agreement, Prof Hawes says: “There is a lot of preparatory work that can be carried out at Pirbright with our microscopes. We can use them to really define the questions we need to answer and then ensure we have samples prepared in a way that will maximise their use at Diamond.”

Diamond, the UK’s national synchrotron, has an embedded cryo-electron microscope facility, known as Electron Bio-Imaging Centre (eBIC). These powerful microscopes are capable of solving protein molecular structures to below 0.3 nm resolution, and are well suited to projects that involve understanding the cell biology of virus-host interactions, as well as how viruses replicate.

The microscopes have also enabled the design of a new vaccine for the foot-and-mouth disease virus (FMDV), through allowing Pirbright scientists to view the outer shell of the vaccine. This vaccine has recently been licensed for further development.

Director of Pirbright, Bryan Charleston comments: “A long and productive association between Pirbright and Diamond exists that has resulted in vital research developments such as the visualisation of the FMDV capsid, bluetongue virus and bovine antibody structures. We hope this agreement will aid our ambition to understand the biology of high consequence viruses and expand the range of programmes exploring solutions to control current and emerging problems.”

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.